Site logo
Site logo
Mobile logo
  • Home
  • About
  • NYC TMS Services
  • NYC Spravato Services
  • Insurance Coverage
  • FAQs
  • Blog
  • Contact

Depression

Depression Non-Invasive Depression Treatment Options NYC: TMS Avoids Antidepressant Side Effects
February 20, 2026in Depression 0 Comments 0 Likes

Non-Invasive Depression Treatment Options NYC: TMS Avoids Antidepressant Side Effects

Living with Depression in New York City can feel overwhelming. Between the fast pace, constant noise, and high demands of daily life, the burden of untreated or poorly treated Depression

by Dr. Bryan Bruno, Medical Director
Depression smiling patient holds coffee mug after TMS treatment alleviates her irritability in Depression
February 5, 2026in Depression 0 Comments 0 Likes

How TMS Can Reduce Patient Irritability in Depression

Major depressive disorder (MDD) is one of the most prevalent mental health conditions in New York City and across the U.S., affecting millions of adults and significantly impacting quality of

by Dr. Bryan Bruno, Medical Director
Depression Scientific Study Experiment with the Psilocybin therapy NYC patients want to use for treatment-resistant depression
January 27, 2026in Depression 0 Comments 0 Likes

Psilocybin Therapy NYC: Why TMS and Spravato Remain Better Treatment Options

For New York patients living with treatment-resistant Depression (TRD), new therapies can feel like rays of hope breaking through the darkness. The highly publicized clinical trial of psilocybin in the

by Dr. Bryan Bruno, Medical Director
Depression Patient sitting in a doctor's office smiling as the physician explains tms coil placement
January 20, 2026in Depression 0 Comments 0 Likes

Precision, Not Price: Effective TMS Coil Placement Doesn’t Require MRI Guidance

Transcranial magnetic stimulation (TMS) has become one of the most effective treatments available for instances of Depression that have not responded to medication. As the technology has advanced, so have

by Dr. Bryan Bruno, Medical Director
Depression A doctor and patient engage in a friendly conversation about esketamine as a glutamate depression treatment
January 14, 2026in Depression 0 Comments 0 Likes

How Esketamine as a Glutamate Depression Treatment is Changing the Landscape of MDD

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, affecting more than 280 million people. While traditional antidepressants have helped millions, about one-third of people with

by Dr. Bryan Bruno, Medical Director
Depression Woman warming up for a morning workout outdoors showing the benefits of exercise for depression
January 9, 2026in Depression 0 Comments 0 Likes

Benefits of Exercise for Depression: On Movement, Esketamine, and TMS

Depression remains one of the most common and disabling conditions worldwide. Researchers and clinicians increasingly recognize that recovery from Depression is not “one-size-fits-all.” For some, talk therapy and medication provide

by Dr. Bryan Bruno, Medical Director
Depression Woman using Spravato after the spravato monotherapy approval
December 12, 2025in Depression 0 Comments 0 Likes

Breakthrough Spravato Monotherapy Approval for Treatment-Resistant Depression

For many people living with Depression, the path to relief is not straightforward. Traditional antidepressants like SSRIs and SNRIs help millions, but some patients don’t respond at all, even after

by Dr. Bryan Bruno, Medical Director
Depression Pharmacist discusses low antidepressant success rates with a patient
November 18, 2025in Depression 0 Comments 0 Likes

Combatting a Low Rate of Long-Term Antidepressant Success with TMS Therapy

For decades, antidepressant medications have been the first-line treatment for major depressive disorder (MDD). While they have helped millions of people, the reality is that they often fall short—with new

by Dr. Bryan Bruno, Medical Director
Depression Happy patient takes spravato after learning how it can help him recover from Depression in the spravato medication guide
November 11, 2025in Depression 0 Comments 0 Likes

Your Spravato Medication Guide: An In-Depth Review for New York City Patients

In New York City, the fast pace and constant pressure can exacerbate Depression—especially for those who’ve tried multiple antidepressants with limited success. That’s why we’ve built out a Spravato medication

by Dr. Bryan Bruno, Medical Director
anxiety Man uses esketamine for anxiety with comorbid depression
November 11, 2025in anxiety 0 Comments 0 Likes

New Hope for NYC: Esketamine for Anxiety and Comorbid Treatment-Resistant Depression

Depression is widespread—and even more so in high-stress environments like New York City. Despite advances in treatment, many patients—especially those contending with treatment-resistant Depression (TRD) and comorbid anxiety–find that standard

by Dr. Bryan Bruno, Medical Director
Prev

Posts navigation

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 11
Next

Recent Posts

  • Non-Invasive Depression Treatment Options NYC: TMS Avoids Antidepressant Side Effects
  • How TMS Can Reduce Patient Irritability in Depression
  • Psilocybin Therapy NYC: Why TMS and Spravato Remain Better Treatment Options
  • Precision, Not Price: Effective TMS Coil Placement Doesn’t Require MRI Guidance
  • How Esketamine as a Glutamate Depression Treatment is Changing the Landscape of MDD

Categories

  • anxiety
  • COVID-19
  • Depression
  • Depression Factors
  • Loneliness
  • Manhattan TMS
  • Resources
  • Support
  • TMS
  • TMS Maintenance
  • Treatment
  • Types of Depression
  • Uncategorized
Site Map
  • Home
  • About
  • Services
  • Insurance Coverage
  • Frequently Asked Questions
  • Blog
Copyright © 2024 Mid City TMS. All rights reserved. Designed by Online Optimism.
280 Madison Ave, Suite 1102, New York, NY 10016
div#stuning-header .dfd-stuning-header-bg-container {background-size: initial;background-position: top center;background-attachment: initial;background-repeat: initial;}#stuning-header div.page-title-inner {min-height: 650px;}#main-content .dfd-content-wrap {margin: -10px;} #main-content .dfd-content-wrap > article {padding: 10px;}@media only screen and (min-width: 1101px) {#layout.dfd-portfolio-loop > .row.full-width > .blog-section.no-sidebars,#layout.dfd-gallery-loop > .row.full-width > .blog-section.no-sidebars {padding: 0 20px;}#layout.dfd-portfolio-loop > .row.full-width > .blog-section.no-sidebars > #main-content > .dfd-content-wrap:first-child,#layout.dfd-gallery-loop > .row.full-width > .blog-section.no-sidebars > #main-content > .dfd-content-wrap:first-child {border-top: 20px solid transparent; border-bottom: 10px solid transparent;}#layout.dfd-portfolio-loop > .row.full-width #right-sidebar,#layout.dfd-gallery-loop > .row.full-width #right-sidebar {padding-top: 10px;padding-bottom: 10px;}#layout.dfd-portfolio-loop > .row.full-width > .blog-section.no-sidebars .sort-panel,#layout.dfd-gallery-loop > .row.full-width > .blog-section.no-sidebars .sort-panel {margin-left: -20px;margin-right: -20px;}}#layout .dfd-content-wrap.layout-side-image,#layout > .row.full-width .dfd-content-wrap.layout-side-image {margin-left: 0;margin-right: 0;}